CRISPR Therapeutics Cash Flow Statement
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics free cash flow
In fiscal 2025, CRISPR Therapeutics generated -$345.0 million of operating cash flow and spent $914,000 on capital expenditures. That left free cash flow of -$345.9 million, a free-cash-flow margin of -9855.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
CRISPR Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -581.60M | -366.25M | -153.61M | -650.17M | 377.66M | -348.87M | 66.86M | -164.98M | -68.36M | -23.20M |
| Net Income growth (YoY) | — | — | — | -272.16% | — | -621.80% | — | — | — | — |
| Depreciation & Amortization | 19.48M | 19.26M | 19.84M | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M | 3.02M | 925.00K |
| Stock-Based Compensation | 72.50M | 86.57M | 81.03M | 97.95M | 102.39M | 66.02M | 44.06M | 34.98M | 18.87M | 10.84M |
| Change in Working Capital | 77.09M | 160.68M | -191.12M | 4.54M | 17.35M | 33.91M | -47.77M | 11.26M | -24.86M | 1.87M |
| Operating Cash Flow | -345.01M | -142.77M | -260.38M | -495.74M | 538.97M | -238.37M | 56.68M | -96.24M | -70.09M | -52.86M |
| Capital Expenditures | -914.00K | -1.90M | -9.47M | -37.19M | -81.70M | -18.36M | -6.68M | -2.77M | -7.81M | -3.02M |
| Investing Cash Flow | -31.80M | -280.48M | 374.65M | -258.65M | -1.04B | -541.17M | 1.32M | -2.77M | -8.31M | 31.88M |
| Share Repurchases | — | — | — | — | — | — | — | -57.00K | — | — |
| Financing Cash Flow | 426.03M | 331.98M | 62.66M | 38.59M | 250.94M | 1.02B | 430.98M | 315.93M | 2.61M | 183.22M |
| Net Change in Cash | 49.30M | -91.29M | 177.01M | -715.88M | -245.52M | 236.66M | 489.00M | 216.90M | -75.76M | 162.01M |
| Free Cash Flow | -345.93M | -144.68M | -269.85M | -532.93M | 457.27M | -256.72M | 49.99M | -99.01M | -77.91M | -55.88M |
This table shows 10 annual periods of CRISPR Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CRSP's reporting calendar. What is a cash flow statement?